Ranbaxy Laboratories Limited : Ranbaxy and EPIRUS Announce Signing of Licensing Agreement for Biosimilar Product

Gurgaon, India, Ranbaxy to market in India and other Emerging Markets, after approval

Ranbaxy Laboratories Limited ("RANBAXY") and EPIRUS Switzerland GmbH, a wholly-owned subsidiary of Boston-based Epirus Biopharmaceuticals, Inc. ("EPIRUS"), announced the signing of a licensing agreement for BOW015, a biosimilar version of Infliximab. The product will be introduced in India and other Emerging Markets. Currently, there is no biosimilar of Infliximab approved in India.

Under the terms of the agreement, EPIRUS will develop and supply the product, and upon regulatory approval Ranbaxy will market the same in India and other emerging markets.

Commenting on the partnership, Sanjeev I Dani, Executive Vice President & Head, Global Strategy, Ranbaxy said, "We are pleased to partner with EPIRUS for Biosimilar Infliximab. We will utilise our strong front-end capabilities in making this product available in India and other parts of the world."

Amit Munshi, President and CEO of EPIRUS commented, "We are very pleased to work with Ranbaxy to register and commercialize this important medicine. Ranbaxy has the right focus and infrastructure in these markets to effectively bring this product to the market".

BOW015 is a biosimilar version of Infliximab, a biologic therapy marketed under the name REMICADE®. EPIRUS recently completed a successful Phase 3 trial which met its predefined endpoint, demonstrating comparability of BOW015 to REMICADE® as measured by ACR20 response in severe rheumatoid arthritis (RA) patients. The study also showed no meaningful differences between BOW015 and REMICADE® with regard to safety or immunogenicity.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 150 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe. For more information, please visit www.ranbaxy.com.

EPIRUS is developing a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins for commercialization in emerging markets. This pipeline is designed for deployment in an In Market, For Market™ manufacturing configuration, which confers strategic and economic advantages in many key markets and regions.

In close partnership with companies in Brazil, South Africa, Russia, Turkey, and other target markets, EPIRUS transfers product technology, designs and builds manufacturing capabilities, navigates local regulatory environments, and commercializes products.

In regions where the In Market, For Market™ strategy is not being pursued Epirus is working with leading commercial partners to license and brings the products to market.

Through coordinated global development and local production of its pipeline, EPIRUS will accelerate patient access to these important medicines.